Patients with the metabolic syndrome and a disturbed cortisol balance display more microalbuminuria

Diabetes and Vascular Disease Research

Volumn 5, Issue 1, 2008, Pages 54-58

  Janssen, Sarah Frederique ^a   Twickler, Theodorus B ^a   Jublanc, Christel ^c   Cramer, Maarten J ^b   Bruckert, Eric ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Disturbed cortisol balance; Metabolic syndrome; Microalbuminuria

Indexed keywords

ALBUMIN; DEXAMETHASONE; HYDROCORTISONE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; HOMEOSTASIS; HORMONE METABOLISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; MORBIDITY; MORTALITY; URINARY EXCRETION;

ADRENOCORTICAL HYPERFUNCTION; ALBUMINURIA; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYDROCORTISONE; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 41949089983     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2008.010     Document Type: Article

References (21)

1. Ljung T, Andersson B, Bengtsson BA, Bjorntorp P, Marin P. Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose-response study. Obes Res 1996;4:277-82.
2. Rosmond R, Dallman MF, Bjorntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab 1998;83:1853-9.
3. Rask E, Ollsson T, Soderberg S et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001;86:1418-21.
4. Rask E, Walker BR, Sodenberg S et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2002;87:3330-6.
5. Arnaldi G, Mancini T, Polenta B, Boscaro M. Cardiovascular risk in Cushing's syndrome. Pituitary 2004;7:253-6.
6. Faggiano A, Pivonello R, Spiezia S et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003;88:2527-33.
7. Bartnik M, Norhammar A, Rydén L. Hyperglycaemia and cardiovascular disease. J Intern Med 2007;262:145-56.
8. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Geneva, WHO 1999 Part 1: Diagnosis and classification of diabetes mellitus.
9. Viardot A, Huber P, Puder JJ, Zulewski H, Keller U, Muller B. Reproducibility of nighttime salivary cortisol and its use in the diagnosis of hypercortisolism compared with urinary free cortisol and overnight dexamethasone suppression test. J Clin Endocrinol Metab 2005;90:5730-6.
10. Findling JW, Raff H, Aron DC. The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome. J Clin Endocrinol Metab 2004;89:1222-6.
11. Naidoo DP. The link between microalbuminuria, endothelial dysfunction and cardiovascular disease in diabetes. Cardiovasc J South Afr 2002;13:194-9.
12. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. MAU is a predictor of clinical nephropathy in type 1 diabetes. Lancet 1982;1:1430-2.
13. Jensen S. Microalbuminuria and risk of atherosclerosis. Clinical epidemiological and physiological investigators. Dan Med Bull 2000;47:63-78.
14. Martin NM, Dhillo WS, Banerjee A et al. Comparison of the dexamethasone-suppressed corticotrophin-releasing hormone test and low dose dexamethasone suppression test in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 2006;91:2582-6.
15. Koh JM, Kim Y, Chung YE et al. Increased urinary albumin excretion in Cushing's syndrome: remission after correction of hypercortisolaemia. Clin Endocrinol 2000;52:349-53.
16. Känel von R, Mausbach BT, Kudielka BM, Orth-Gomér K. Relation of morning serum cortisol to prothrombotic activity in women with stable coronary artery disease. J Thromb Thrombolysis 2007 Jun 12 Epub ahead of print.
17. Turgut O, Yilmaz A, Yalta K, Karadas F, Birha Yilmaz M. Gamma-glutamyltransferase is a promising biomarker for cardiovascular risk. Med Hypothese 2006;67:1060-4.
18. Morange PE, Aubert J, Peiretti F et al. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diab 1999;48:890-5.
19. De Pergola G, De Mitrio V, Cignarelli M et al. Inverse relationship between cortisol excretion rate and plasminogen activator inhibitor-1 (PAI-1) antigen and activity in premenopausal obese women. Int J Obes 1991;15:619-22.
20. Chandler WL, Mornin D, Whitten RO et al. Insulin, cortisol and catecholamines do not regulate circadian variations in fibrinolytic activity. Thromb Res 1990;58:1-12.
21. Aillaud MF, Juhan-Vague I, Alessi MC et al. Increased PA-inhibitor levels in the postoperative period - no cause-effect relation with increased cortisol. Thromb Haemost 1985;54:466-8.